AbbVie will present upadacitinib in the SELECT-COMPARE, SELECT-PsA 1 and SELECT-AXIS 2 studies at the European League Against Rheumatism (EULAR) conference in Milan between May 31 and June 3. It announced on the 24th that new long-term data will show the efficacy and safety profile of the drug is released.
“New data from the SELECT study program presented today expands the evidence for Rinvoq’s efficacy and safety profile in several rheumatologic conditions,” said Mudra Kapoor, MD, Vice President, Global Medicine, Immunology for AbbVie. “AbbVie’s investment in long-term data is part of our ongoing efforts to help patients with immune-mediated diseases.”
The long-term data supporting Rinvoq’s efficacy and safety profile, to be presented at the European Society of Rheumatology conference, includes data from more than 20 clinical endpoints and safety data from around 2,450 patients across rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis More than 6,700 patient years of data are included.
“Rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis,” said Professor Roy M. “The effects of these diseases can last a lifetime and have a significant impact on a patient’s quality of life,” he said. which can help you improve your skills.”
Meanwhile, important studies are ‘long-term safety and efficacy of upadacitinib or adalimumab in rheumatoid arthritis patients: 5-year data from the SELECT-COMPARE study’, ‘long-term efficacy and safety of upadacitinib in patients with psoriatic arthritis: a phase 3 3-year study data SELECT-PsA 1’, ‘Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis inadequately responsive to biologic antirheumatic agents: first-year results of a phase 3 study’.
.jpg?fit=300%2C300&ssl=1)
